VTAK Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.0M
+135.9%
432.0K
+81.5%
238.0K
+5.3%
226.0K
+6.6%
212.0K
Cost of Revenue
921.0K
+2092.9%
42.0K
+110.0%
20.0K
+11.1%
18.0K
+28.6%
14.0K
Gross Profit
98.0K
-74.9%
390.0K
+78.9%
218.0K
+4.8%
208.0K
+5.1%
198.0K
Operating Expenses
4.1M
+49.7%
2.7M
-12.2%
3.1M
-4.5%
3.2M
-33.9%
4.9M
R&D
142.0K
-4.7%
149.0K
-54.6%
328.0K
+18.8%
276.0K
-86.2%
2.0M
SG&A
3.9M
+52.8%
2.6M
-7.1%
2.8M
-6.7%
3.0M
+2.5%
2.9M
Operating Income
-3955000
-70.6%
-2318000
+19.1%
-2866000
+5.1%
-3021000
+35.5%
-4686000
EBITDA
-3573000
-86.8%
-1913000
+18.2%
-2339000
+6.2%
-2493000
+40.7%
-4201000
Net Income
-3306000
-95.6%
-1690000
+71.1%
-5848000
-149.5%
-2344000
+57.1%
-5458000
EPS (Basic)
$-0.92
+33.8%
$-1.39
+59.0%
$-3.39
-99.4%
$-1.70
+76.6%
$-7.28
EPS (Diluted)
$-0.92
+33.8%
$-1.39
+59.0%
$-3.39
-99.4%
$-1.70
+76.6%
$-7.28
Shares (Diluted)
2.8M
+26.3%
2.2M
+28.5%
1.7M
+29.2%
1.3M
+88.1%
701.9K
Catheter Precision (VTAK) โ€” Financials